How can companies successfully engage with stakeholders to support better access to treatment for patients? In this Pharmaceutical Executive article, Andrew Butcher and Brian Kennedy, Executive Director of Alliance for Patient Access, outline six steps that help maximize the prospects for success in light of the evolving dynamics in stakeholder relationships.
Click here to read the article.
Part 2: Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Healthcare coverage is heterogeneous across emerging markets, with public funding limited by budgetary constraints. This typically sees higher-priced drugs,...